Synthesis and characterization of some new 2(3H)-benzoxazolones with analgesic and antiinflammatory activities

References

• G Dannhardt, and W Kiefer. (2001). Cyclooxygenase inhibitors-current status and future prospects. Eur J Med Chem 36:109–126.
   PubMed Web of Science ®Google Scholar
• TD Penning, JJ Talley, SR Bertenshaw, JS Carter, PW Collins, S Docter, MJ Graneto, LF Lee, JW Malecha, JM Miyashiro, RS Rogers, DJ Rogier, SS Yu, GD Anderson, EG Burton, JN Cogburn, SA Gregory, CM Koboldt, WE Perkins, K Seibert, AW Veenhuizen, YY Zhang, and PC Isakson. (1997). Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). J Med Chem 40:1347–1365.
   PubMed Web of Science ®Google Scholar
• P Prasit, Z Wang, C Brideau, CC Chan, S Charleson, W Cromlish, D Ethier, JF Evans, AW Ford-Hutchinson, JY Gauthier, R Gorgon, J Guay, M Gresser, S Kargman, B Kennedy, Y Leblanc, S Léger, J Mancini, GP O'Neill, M Ouellet, MD Percival, H Perrier, D Riendeau, I Rodger, P Tagari, M Thérien, P Vickers, E Wong, LJ Xu, RN Young, and R Zamboni. (1999). The discovery of rofecoxib [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor. Bioorg Med Chem Lett 9:1773–1778.
   PubMed Web of Science ®Google Scholar
• P Jüni, L Nartey, S Reichenbach, R Sterchi, PA Dieppe, and M Egger. (2004). Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet 364:2021–2029.
   PubMed Web of Science ®Google Scholar
• Alert for Healthcare Professionals Valdecoxib (marketed as Bextra). Available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/valdecoxibHCP.htm. Accessed June 24, 2005.
   Google Scholar
• H Erdoğan, M Debaert, and J Cazin. (1991). Synthesis of some 2-benzoxazolinone derivatives and their analgesic properties. Arzneim-Forsch/Drug Res 41:73–76.
   PubMed Web of Science ®Google Scholar
• E Palaska, S Ünlü, F Özkanlı, G Pilli, H Erdoğan, C Şafak, R Demirdamar, and B Gümüşel. (1995). 3-substituted piperazinomethyl benzoxazolinones: Analgesic and antiinflammatory compounds inhibiting prostaglandin E2. Arzneim-Forsch/Drug Res 45:693–697.
   PubMedGoogle Scholar
• N Gökhan, H Erdoğan, BC Tel, and R Demirdamar. (1996). Analgesic and antiinflammatory activity screening of 6-acyl-3-piperazinomethyl-2-benzoxazolinone derivatives. Eur J Med Chem 31:625–628.
   Google Scholar
• N Gökhan, H Erdoğan, NT Durlu, and R Demirdamar. (1999). Novel antiinflammatory analgesics: 3-(2-/4-Pyridylethyl)-benzoxazolinone and oxazolo[4,5-b]pyridin-2-one derivatives. Arch Pharm 332:43–49.
   PubMedGoogle Scholar
• S Unlu, T Onkol, Y Dundar, B Okcelik, E Kupeli, E Yesilada, N Noyanalpan, and MF Sahin. (2003). Synthesis and analgesic and anti-inflammatory activity of some new (6-acyl-2-benzoxazolinone and 6-acyl-2-benzothiazolinone derivatives with acetic acid and propanoic acid residues. Arch Pharm 336:353–360.
   PubMed Web of Science ®Google Scholar
• E Banoglu, B Okcelik, E Kupeli, S Unlu, E Yesilada, M Amat, JF Caturla, and MF Sahin. (2003). Amide derivatives of [5-chloro-6-(2-chloro/fluorobenzoyl)-2-benzoxazolinone-3-yl]acetic acids as potential analgesic and anti-inflammatory compounds. Arch Pharm 336:251–257.
   PubMedGoogle Scholar
• N Gökhan, H Erdoğan, NT Durlu, R Demirdamar, and M Özalp. (2003). Synthesis and evaluation of analgesic, antiinflammatory and antimicrobial activities of 6-acyl-3-piperazinomethyl-2-benzoxazolinones. Arzneim-Forsch/Drug Res 53:114–120.
   PubMedGoogle Scholar
• Z Soyer, M Bas, A Pabuççuoğlu, and V Pabuççuoğlu. (2005). Synthesis of some 2(3H)-benzoxazolone derivatives and their in vitro effects on human leukocyte myeloperoxidase activity. Arch Pharm 338:405–410.
   PubMed Web of Science ®Google Scholar
• M Köksal, N Gökhan, E Küpeli, E Yeşilada, and H Erdoğan. (2005). Synthesis, analgesic and antiinflammatory of certain 5-/6-acyl-3-(4-substituted-1-piperazinylmethyl)-2-benzoxazolinones derivatives. Arch Pharm 338:117–125.
   PubMed Web of Science ®Google Scholar
• B Ökçelik, S Ünlü, E Banoğlu, E Küpeli, E Yeşilada, and MF Şahin. (2003). Investigations of new pyridazinone derivatives for the synthesis of potent analgesic and anti-inflammatory compounds with cyclooxygenase inhibitory activity. Arch Pharm 336:406–412.
   PubMed Web of Science ®Google Scholar
• S Ünlü, S Nacak Baytaş, E Küpeli, and E Yeşilada. (2003). Studies on novel 7-acyl-5-chloro-2-oxo-3H-benzoxazole derivatives as potential analgesic and anti-inflammatory agents. Arch Pharm 336:310–321.
   PubMedGoogle Scholar
• J Weinstock, DE Gaitanopoulos, OD Stringer, RG Franz, JP Hieble, LB Kinter, WA Mann, KE Flaim, and G Gessner. (1987). Synthesis and evaluation of non-catechol D-1 and D-2 dopamine receptor agonist: Benzimidazol-2-one, benzoxazol-2-one and the highly potent benzothiazol-2-one 7-ethylamines. J Med Chem 30:1166–1176.
   PubMedGoogle Scholar
• W Von der Saal, JP Hölck, W Kampe, A Metens, and B Müller-Beckmann. (1989). Nonsteroidal cardiotonics 2. The initropic activity of linear tricycic 5,6,5 fused heterocycles. J Med Chem 32:1481–1491.
   PubMedGoogle Scholar
• JP Bonte, JP Piancastelli, MCI Lesieur, JC Lamar, M Beaughard, and G Dureng. (1990). Amino ketone and amino alcohol derivatives of benzoxazolinone: Synthesis, adrenergic and antihypertensive properties. Eur J Med Chem 25:361–368.
   Google Scholar
• Y Katsura, S Nishino, and H Takasugi. (1991). Studies on antiulcer drugs. I. Synthesis and antiulser activities of imidazo[1,2-a]pyridinyl-2-oxobenzoxazolidines-3-oxo-1,4-benzoxazines and related compounds. Chem Pharm Bull 39:2937–2943.
   PubMed Web of Science ®Google Scholar
• WJ Close, BD Tiffany, and MA Spielman. (1949). The analgesic activity of some benzoxazolone derivatives. J Am Chem Soc 71:1265–1268.
   PubMed Web of Science ®Google Scholar
• M Köksal, N Gökhan, H Erdoğan, M Özalp, and M Ekizoğlu. (2002). Synthesis of 3-(4-substituted benzoylmethyl)-2-benzoxazolinones and screening antimicrobial activities. II Farmaco 57:535–538.
   PubMedGoogle Scholar
• Y Kasahara, H Hikino, S Tsurufuji, M Watanabe, and K Ohuchi. (1985). Antiinflammation actions of ephedrines in acute inflammations. Planta Med 51:325–331.
   PubMed Web of Science ®Google Scholar
• R Koster, M Anderson, and EJ de Beer. (1959). Acetic acid for analgesic screening. Fed Proc 18:412.
   Google Scholar
• JH Rosland, SO Hunskaar, OJ Broch, and K Hole. (1992). Acute and long term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in tests of nociception in mice. Pharmacol Toxicol 70:31–37.
   PubMedGoogle Scholar
• K Tsurumi, K Kyuki, M Niwa, S Kokuba, and H Fujimura. (1986). Pharmacological investigations of the new antiinflammatory agent 2-(10,11-dihydro-10-oxodibenzo[b,f]thiepin-2-yl)propionic acid. Arzneim Forsch/Drug Res 36:1796–1803.
   PubMed Web of Science ®Google Scholar
• A Gavalas, L Kourounakis, D Litina, and P Kourounakis. (1991). Anti-inflammatory and immuno-modulating effects of the novel agent γ-(2-aminoethylamino)-2-butyrothienone. Inhibitory effects on mouse paw oedema. Arzneim Forsch/Drug Res 41:423–426.
   PubMedGoogle Scholar